Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | QS21 + TG01 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| QS21 | QS-21|QS 21 | |||
| TG01 | TG-01|TG 01 | TG01 is a peptide-based cancer vaccine consisting of 7 RAS peptides specific to KRAS G12 and G13 mutations, which potentially induces RAS-specific antitumor immune response (PMID: 32063605). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05841550 | Phase Ib/II | QS21 + TG01 | The TG01 Study With TG01/QS-21 Vaccine in Patients With High-risk Smouldering Multiple Myeloma and Multiple Myeloma | Recruiting | NOR | 0 |
| NCT05638698 | Phase II | Balstilimab + QS21 + TG01 QS21 + TG01 | Tg01 Vaccine / Qs-21 Stimulon™ With Or Without Balstilimab As Maintenance Therapy Following Adjuvant Chemotherapy In Patients With Resected Pancreatic Cancer (TESLA) | Active, not recruiting | USA | 0 |